KRAS and non-small cell lung carcinoma: The absence of checkpoint marker expression in pre clinical models of KRAS;LKB1 mutant NSCLC corresponded with poor to no responsiveness to checkpoint immunotherapy, and effective treatments to durably target tumors that are non-responsive to immunotherapy or TKIs remain lacking (Skoulidis et al., 2018; Li et al., 2022).